This story has been updated to provide comments from Trovagene's management made during a conference call with investors.

NEW YORK (GenomeWeb) – Trovagene reported after the close of the market on Thursday that its fourth quarter revenues rose 41 percent year over year.

The liquid biopsy MDx developer said its revenues rose to $79,000 for the three months ended Dec. 31, 2015, up from $56,000 in Q4 2014. However, the revenues significantly missed analysts' estimates of $100,000 for the quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

Wired reports that 23andMe is trying to bolster its outside collaborations.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.